硫唑嘌呤与泼尼松联用对视神经脊髓炎谱系疾病的临床疗效及其对复发的影响

Clinical Efficacy of Azathioprine Combined with Prednisone in Patients with Optic Neuromyelitis Disease and Its Influence on Recurrense

目的:探究硫唑嘌呤与泼尼松联用对视神经脊髓炎谱系疾病的临床疗效及其对复发的影响。方法:选取2014年11月—2017年11月间收治的视神经脊髓炎谱系疾病患者94例资料,按治疗方法的不同将其分为治疗组和对照组,每组47例;对照组患者给予单用泼尼松治疗,治疗组患者在对照组基础上加用硫唑嘌呤治疗,比较两组患者临床治疗后的复发次数、EDSS评分值和用药期间不良反应反应率的差异。结果:治疗6月EDSS评分值降低程度均明显优于对照组(P<0.05);随着时间延长两组患者平均复发次数均逐渐增多,治疗组治疗3月、6月、12月时的平均复发次数均明显少于对照组(P<0.05);用药期间不良反应(肝功能损伤、血小板减少、恶心呕吐等)发生率(12.77%)明显低于对照组(40.43%)(P<0.05)。结论:硫唑嘌呤与泼尼松联用于治疗视神经脊髓炎谱系疾病患者的疗效较为明显,有效降低了患者EDSS评分值和复发次数,且安全性高。

Objective: To investigate the clinical efficacy of azathioprine combined with prednisone in patients with optic neuromyelitis disease and its influence on recurrense. Methods: Data of 94 cases of patients with optic neuromyelitis spectrum disease admitted between November 2014 and November 2017 were selected. According to different treatment methods,they were divided into treatment group and control group,with 47 cases in each group. Patients in the control group were given with prednisone alone,while patients in the treatment group were treated with azathioprine on the basis of the control group. The differences of recurrence frequency,EDSS score value and adverse reaction rate during medication between the two groups were compared. Results: The EDSS scores at 6 months after treatment were significantly lower than those in the control group (P<0.05). With the extension of time,the average recurrence frequency of patients in the two groups was increased gradually,and the average recurrence frequency in the treatment group at 3 months, 6 months and 12 months was significantly lower than that in the control group (P<0.05). The incidence of adverse drug reactions (liver function injury, thrombocytopenia, nausea vomiting, etc.) during the medication period (12.77%) was significantly lower than that of the control group (40.43%)(P<0.05). Conclusion: Azathioprine combined with prednisone showed an obvious therapeutic effect in patients with optic neuromyelitis spectrum disease, the EDSS score and recurrence frequency were effectively reduced,and had a high safety.